{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:17:22Z","timestamp":1768529842400,"version":"3.49.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.semarthrit.2011.05.003","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T21:17:03Z","timestamp":1323465423000},"page":"524-533","source":"Crossref","is-referenced-by-count":35,"title":["Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review"],"prefix":"10.1016","volume":"41","author":[{"given":"Mar\u00eda","family":"Cruz Fern\u00e1ndez-Espartero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"P\u00e9rez-Zafrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.410300510","article-title":"Anti-tumor necrosis factor therapy abrogates autoimmune demyelination","volume":"30","author":"Selmaj","year":"1991","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.05.003_bib2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/eji.1830240916","article-title":"Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins","volume":"24","author":"Baker","year":"1994","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.05.003_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.170.2.607","article-title":"Tumor necrosis factor identified in multiple sclerosis brain","volume":"170","author":"Hofman","year":"1989","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.05.003_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.05.003_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-G","article-title":"Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis","volume":"32","author":"Maimone","year":"1991","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.05.003_bib6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI115102","article-title":"Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions","volume":"87","author":"Selmaj","year":"1991","journal-title":"J Clin Invest"},{"issue":"6 Suppl 6","key":"10.1016\/j.semarthrit.2011.05.003_bib7","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/WNL.45.6_Suppl_6.S44","article-title":"Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors","volume":"45","author":"Selmaj","year":"1995","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.semarthrit.2011.05.003_bib8","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.05.003_bib9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.05.003_bib10","first-page":"985","article-title":"Retrobulbar optic neuritis associated with infliximab","volume":"120","author":"Foroozan","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.05.003_bib11","first-page":"169","article-title":"Rheumatoid arthritis and multiple sclerosis in the same patient","volume":"66","author":"Attout","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.05.003_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clineuro.2005.11.025","article-title":"CNS demyelination in autoimmune diseases","volume":"108","author":"Brinar","year":"2006","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.1996.tb00004.x","article-title":"Multiple sclerosis and chronic inflammatory diseases","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib14","first-page":"1027","article-title":"Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance","volume":"33","author":"Toussirot","year":"2006","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.05.003_bib15","first-page":"178","article-title":"TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries","volume":"65","author":"Nasir","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib16","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.05.003_bib17","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.05.003_bib21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.05.003_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054772","article-title":"Frequency of multiple sclerosis in Menorca","volume":"20","author":"Casquero","year":"2001","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1600-0404.1998.tb07302.x","article-title":"Multiple sclerosis in Mostoles, central Spain","volume":"98","author":"Benito-Leon","year":"1998","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.05.003_bib24","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s00415-002-0841-y","article-title":"Epidemiology of multiple sclerosis in the Canary Islands (Spain): a study on the island of La Palma","volume":"249","author":"Hernandez","year":"2002","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.05.003_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s004150050070","article-title":"Prevalence of multiple sclerosis in the province of Teruel","volume":"244","author":"Modrego Pardo","year":"1997","journal-title":"Spain J Neurol"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.05.003_bib26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1442-9071.2007.01541.x","article-title":"Etanercept associated optic neuropathy","volume":"35","author":"Chang","year":"2007","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.05.003_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor alpha therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2011.05.003_bib29","first-page":"2079","article-title":"Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis","volume":"31","author":"Richette","year":"2004","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2011.05.003_bib30","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.10488","article-title":"Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al","volume":"46","author":"Cisternas","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2710.2006.00779.x","article-title":"Adverse effect of TNF-alpha blocker?","volume":"31","author":"Cay","year":"2006","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.05.003_bib32","first-page":"1457","article-title":"Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab","volume":"33","author":"Ruiz-Jimeno","year":"2006","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","article-title":"Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis","volume":"39","author":"Enayati","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archneurol.2009.49","article-title":"A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis","volume":"66","author":"Rovira","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.semarthrit.2011.05.003_bib35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.05.003_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/rheumatology\/41.1.88","article-title":"The prevalence of rheumatoid arthritis in the general population of Spain","volume":"41","author":"Carmona","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2011.05.003_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.iy.10.040192.001101","article-title":"Immunological aspects of demyelinating diseases","volume":"10","author":"Martin","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semarthrit.2011.05.003_bib38","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.0105-2896.2005.00240.x","article-title":"Multiple sclerosis","volume":"204","author":"Hafler","year":"2005","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib39","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar2561","article-title":"Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort","volume":"10","author":"Gonzalez-Alvaro","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2011.05.003_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib41","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.semarthrit.2011.05.003_bib42","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.05.003_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nbd.2004.07.015","article-title":"Genes, environment, and susceptibility to multiple sclerosis","volume":"17","author":"Sotgiu","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R","article-title":"Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis","volume":"45","author":"van Boxel-Dezaire","year":"1999","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/03009740802136164","article-title":"Multiple sclerosis following etanercept treatment for ankylosing spondylitis","volume":"37","author":"Pfueller","year":"2008","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1442-9071.2008.001741.x","article-title":"Ophthalmic manifestations of demyelination secondary to etanercept","volume":"36","author":"Do","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.05.003_bib47","first-page":"1469","article-title":"Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies","volume":"35","author":"Davis","year":"2008","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10165-008-0062-z","article-title":"A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy","volume":"18","author":"Kameda","year":"2008","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.20452\/pamw.370","article-title":"Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept","volume":"118","author":"Kur-Zalewska","year":"2008","journal-title":"Pol Arch Med Wewn"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard.2005.043208","article-title":"Guillain-Barre syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature","volume":"67","author":"Silburn","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1-2","key":"10.1016\/j.semarthrit.2011.05.003_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000109576","article-title":"Multiple sclerosis onset during etanercept treatment","volume":"59","author":"Gomez-Gallego","year":"2008","journal-title":"Eur Neurol"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.05.003_bib52","first-page":"109","article-title":"Retrobulbar optic neuritis associated with Infliximab","volume":"82","author":"Bidaguren","year":"2007","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.05.003_bib53","first-page":"239","article-title":"Adalimumab-associated multiple sclerosis","volume":"34","author":"Bensouda-Grimaldi","year":"2007","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/03009740600557249","article-title":"Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis","volume":"35","author":"Martinez-Taboada","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib55","first-page":"1202","article-title":"Etanercept induced multiple sclerosis and transverse myelitis","volume":"33","author":"Al Saieg","year":"2006","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2011.05.003_bib56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10067-006-0317-z","article-title":"Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment","volume":"26","author":"Tektonidou","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.05.003_bib57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaapos.2005.12.002","article-title":"Optic neuritis associated with etanercept therapy for juvenile arthritis","volume":"10","author":"Tauber","year":"2006","journal-title":"J AAPOS"},{"issue":"1-2","key":"10.1016\/j.semarthrit.2011.05.003_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","article-title":"Adalimumab-associated optic neuritis","volume":"244","author":"Chung","year":"2006","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib59","first-page":"1018","article-title":"Neurological complications of infliximab","volume":"33","author":"Jarand","year":"2006","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib60","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-005-0097-x","article-title":"New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients","volume":"25","author":"Tanno","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"19","key":"10.1016\/j.semarthrit.2011.05.003_bib61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0025-7753(05)72181-3","article-title":"Multiple sclerosis after treatment with anti-TNF-alpha antibodies","volume":"125","author":"Munteis-Olivas","year":"2005","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00415-005-0055-1","article-title":"CNS demyelination during anti-tumor necrosis factor alpha therapy","volume":"253","author":"Bellesi","year":"2006","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.semarthrit.2011.05.003_bib63","first-page":"374","article-title":"Brachial plexitis and myelitis and herpes-zoster lumbar plexus disorder in patient treated with infliximab","volume":"20","author":"Arias","year":"2005","journal-title":"Neurologia"},{"issue":"6","key":"10.1016\/j.semarthrit.2011.05.003_bib64","first-page":"1548","article-title":"Anti-tumor necrosis factor alpha-associated multiple sclerosis","volume":"26","author":"Titelbaum","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.semarthrit.2011.05.003_bib65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1155\/2005\/358658","article-title":"Demyelination-like syndrome in Crohn's disease after infliximab therapy","volume":"19","author":"Freeman","year":"2005","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.05.003_bib66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/03009740510017887","article-title":"Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease","volume":"34","author":"Kunzmann","year":"2005","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2011.05.003_bib67","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","article-title":"Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers","volume":"64","author":"Richez","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.semarthrit.2011.05.003_bib68","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1085-9489.2005.00053.x","article-title":"Multifocal motor neuropathy during treatment with infliximab","volume":"10","author":"Cocito","year":"2005","journal-title":"J Peripher Nerv Syst"},{"issue":"12","key":"10.1016\/j.semarthrit.2011.05.003_bib69","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1345\/aph.1G279","article-title":"Optic neuritis with concurrent etanercept and isoniazid therapy","volume":"39","author":"Noguera-Pons","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.semarthrit.2011.05.003_bib70","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/rheumatology\/keh439","article-title":"Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy","volume":"44","author":"Rodriguez-Escalera","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"7389","key":"10.1016\/j.semarthrit.2011.05.003_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.326.7389.579","article-title":"Bilateral anterior toxic optic neuropathy and the use of infliximab","volume":"326","author":"ten Tusscher","year":"2003","journal-title":"BMJ"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017211001442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017211001442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T11:59:14Z","timestamp":1742039954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017211001442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0049017211001442"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2011.05.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}